Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleThe treatment of spasticity with Delta(9)-tetrahydrocannabinol in persons with spinal cord injury.
Author(s)Hagenbach U, Luz S, Ghafoor N, Berger JM, Grotenhermen F, Brenneisen R, Mader M.
Journal, Volume, IssueSpinal Cord. 2006 Oct 17; [Epub ahead of print]
Major outcome(s)Significant improvement of spasticity with THC
IndicationSpasticity;Spinal cord injuryAbstract

Study design:Open label study to determine drug dose for a randomized double-blind placebo-controlled parallel study.Objectives:To assess the efficacy and side effects of oral Delta(9)-tetrahydrocannabinol (THC) and rectal THC-hemisuccinate (THC-HS) in SCI patients.Setting:REHAB Basel, Switzerland.
Method:Twenty-five patients with SCI were included in this three-phase study with individual dose adjustment, each consisting of 6 weeks. Twenty-two participants received oral THC open label starting with a single dose of 10 mg (Phase 1, completed by 15 patients). Eight subjects received rectal THC-HS (Phase 2, completed by seven patients). In Phase 3, six patients were treated with oral THC and seven with placebo. Major outcome parameters were the spasticity sum score (SSS) using the Modified Ashworth Scale (MAS) and self-ratings of spasticity.
Results:Mean daily doses were 31 mg with THC and 43 mg with THC-HS. Mean SSS for THC decreased significantly from 16.72 (+/-7.60) at baseline to 8.92 (+/-7.14) on day 43. Similar improvement was seen with THC-HS. We observed a significant improvement of SSS with active drug (P=0.001) in the seven subjects who received oral THC in Phase 1 and placebo in Phase 3. Major reasons for drop out were increase of pain and psychological side effects.
Conclusion:THC is an effective and safe drug in the treatment of spasticity. At least 15-20 mg per day were needed to achieve a therapeutic effect.

Dose(s)mean 33 mg per day
Duration (days)43
Participants25 patients with spasticity due to spinal cord injury
DesignOpen study
Type of publicationMedical journal
Address of author(s)REHAB Basel, Centre for Spinal Cord Injury (SCI) and Severe Head Injury (SHI), Basel, Switzerland.
Full text

[Back to Overview]  [IACM Homepage]